Last update 01 Nov 2024

BDTX-1535

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (US)
Login to view timeline

Structure

Molecular FormulaC30H30ClFN6O2
InChIKeyLMOVDLRMIRLIJF-TUVXKDNKSA-N
CAS Registry2607829-38-7

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell Squamous CarcinomaPhase 2
US
31 Mar 2022
EGFR positive non-small cell lung cancerPhase 2
US
31 Mar 2022
GlioblastomaPhase 2
US
31 Mar 2022
metastatic non-small cell lung cancerPhase 2
US
31 Mar 2022
Secondary malignant neoplasm of lungPhase 2
US
31 Mar 2022
Non-Small Cell Lung CancerPhase 2
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
27
BDTX-1535 200 mg
(wadhylulfo) = yosyohyhmb heeignnccw (yiigckkusn )
Positive
23 Sep 2024
BDTX-1535 200 mg
(either C797S or P-loop alpha-C helix compressing (PACC, a major subset of NCMs))
(wadhylulfo) = qowunxndui heeignnccw (yiigckkusn )
Phase 1
22
(ujfyoujrcu) = consistent with the EGFR tyrosine kinase inhibitor (TKIs) class of drugs, including primarily Grade 1 and 2 diarrhea and rash grpbduftvy (kkhyszymoc )
Positive
13 Dec 2023
Phase 1
-
(zxdhdavwgl) = No patients experienced dose limiting toxicity at 15-200 mg QD doses. One of 15 patients treated at the 300 mg QD dose experienced dose limiting diarrhea and 5 of 12 patients at the 400 mg QD dose experienced dose limiting toxicity (diarrhea, 2 patients; rash, stomatitis, fatigue and decreased appetite, 1 patient each). yqoegtmlwv (tjrsqntzde )
Positive
27 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free